<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303468</url>
  </required_header>
  <id_info>
    <org_study_id>NL73194.081.20</org_study_id>
    <nct_id>NCT04303468</nct_id>
  </id_info>
  <brief_title>Intervention With a GABA Supplement in Prediabetics</brief_title>
  <official_title>The Effects of a GABA Supplement Versus a Placebo on Glucose Tolerance and Blood Pressure in Prediabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nunhems</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agrico Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Avebe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this double-blind parallel placebo controlled intervention study the effects of 3 times
      daily 500 mg gamma-aminobutyric acid (GABA) supplementation on glucose tolerance and
      cardiovascular health will be assessed in prediabetics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo controlled double blind parallel study design</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial glycaemic response during a 2 hour oral glucose tolerance test (OGTT)</measure>
    <time_frame>blood will be drawn at baseline and after 30, 60 and 120 minutes, before and after the 12 weeks intervention</time_frame>
    <description>A 2 hour oral glucose tolerance test with 75gr glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial insulin and glucagon response during a 2 hour OGTT,</measure>
    <time_frame>blood will be drawn at baseline and after 30, 60 and 120 minutes, before and after the 12 weeks intervention</time_frame>
    <description>A 2 hour oral glucose tolerance test with 75gr glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma free fatty acids</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>5 days during which they eat their habitual diet, before and after the 12 weeks intervention</time_frame>
    <description>The participants wear a flash glucose monitoring sensor with which their interstitial glucose is measured every 15 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Dynamic measurement: 24 hours, before and after the 12 weeks intervention</time_frame>
    <description>Single measurement and a dynamic measurement:
Mean day systolic and diastolic blood pressure
Mean night systolic and diastolic blood pressure
Time below or above 120/80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrion of markers of inflammation in blood</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
    <description>C-reactive protein and cytokines like IL-6 and TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of triglycerides in blood</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of LDL and HDL cholesterol in blood</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of ALAT and ASAT in blood</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute effects of GABA on postprandial glucose</measure>
    <time_frame>2 hours, after a single administration of 500 mg GABA</time_frame>
    <description>Assessed with an OGTT during which interstitial glucose is measured with flash glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute effects of GABA on blood pressure</measure>
    <time_frame>for 24 hours during which GABA is taken 3 times, each time before the main meal</time_frame>
    <description>Assessed with an ambulatory blood pressure monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI) questionnaire, the outcome is a global PSQI score (range: 0-21), with higher scores indicating poorer sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feelings of depression</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
    <description>Patient Health Questionnaire (PHQ-9), the higher the score the more depressed a person is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feelings of anxiety</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
    <description>General Anxiety Disorder (GAD-7) questionnaire, the higher the score, the more anxious a person is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma GABA concentration</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glutamate concentration</measure>
    <time_frame>before and after the 12 weeks intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Prediabetes</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>GABA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GABA is a nutrient commonly present in our diet in for example tomatoes and potatoes. It is also commercially sold as dietary supplement. A dose of 500 mg, 3 times daily is used</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo consists of capsules containing powdered cellulose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GABA</intervention_name>
    <description>The dietary supplement GABA will be taken orally 3 times daily, before each main meal</description>
    <arm_group_label>GABA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gelatin capsule containing powdered cellulose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 50 and 70

          -  BMI higher or equal to 27 kg/m2

          -  Impaired fasting glucose (fasting glucose ≥ 5.6 and ≤ 6.9 mmol/L) or/and

          -  Impaired glucose tolerance (glucose levels ≥ 7.8 and ≤ 11.1 mmol/L, 2-hours after an
             OGTT or/and glucose levels ≥8.6 mmol/L, 1-hour after an OGTT)

        Exclusion Criteria:

          -  Has been diagnosed with diabetes

          -  Having other conditions, like liver, pancreatic, cardiovascular, gastro-intestinal or
             endocrine diseases, that could influence the study results

          -  Use of medications or supplements that could influence the study results

          -  Sensitive to medical skin adhesives

          -  More than 5kg weight change in the past 12 weeks

          -  Excessive alcohol consumption (&gt;21 glasses/week for men and &gt;14 glasses/week for women
             on average)

          -  Being an employee of Wageningen University, division Human Nutrition and Health

          -  Currently a research subject in other research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renger Witkamp, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tessa de Bie, MSc</last_name>
    <phone>0317481100</phone>
    <email>tessa.debie@wur.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wageningen University, Division of Human Nutrition</name>
      <address>
        <city>Wageningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

